VIR - JP Morgan cuts Vir to neutral cites hepatitis drug franchise concerns
2024-01-29 14:19:18 ET
More on Vir Biotechnology
- Sticking With Vir Biotechnology
- Vir Biotechnology: A Relentless Slide In The Stock, Unresponsive To Positive Developments
- Vir Biotechnology, Inc. (VIR) Q3 2023 Earnings Call Transcript
- Vir Biotechnology to shed 12% of workforce as part of corporate restructuring
- Vir Biotechnology GAAP EPS of -$1.22 beats by $0.03, revenue of $2.6M misses by $6.17M